Konstantinos P Imprialos

List of Publications by Year
in descending order

Version: 2024-02-01

88 papers	1,337 citations	471371 17 h-index	395590 33 g-index
88 all docs	88 docs citations	88 times ranked	1988 citing authors

#	Article	IF	Citations
1	Pseudohyperaldosteronism due to mumijo consumption during pregnancy: a licorice-like syndrome. Gynecological Endocrinology, 2024, 34, 1019-1021.	0.7	13
2	The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease. Angiology, 2022, 73, 000331972110055.	0.8	0
3	Assessment of skin microcirculation in primary aldosteronism: impaired microvascular responses compared to essential hypertensives and normotensives. Journal of Human Hypertension, 2022, 36, 1066-1071.	1.0	4
4	Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients withÂtype 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic. Kardiologia Polska, 2022, 80, 80-82.	0.3	0
5	Impact of Primary Aldosteronism in Resistant Hypertension. Current Hypertension Reports, 2022, , 1.	1.5	2
6	Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study. Kardiologia Polska, 2022, 80, 696-698.	0.3	1
7	Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. American Journal of Cardiology, 2021, 138, 116-118.	0.7	1
8	Female Sexual Dysfunction: A Problem Hidden in the Shadows. Current Pharmaceutical Design, 2021, 27, 3762-3774.	0.9	7
9	Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia. Current Vascular Pharmacology, 2021, 19, 449-450.	0.8	2
10	Primary Aldosteronism: Novel Insights. Current Hypertension Reviews, 2020, 16, 19-23.	0.5	8
11	Hypertension in Metabolic Syndrome: Novel Insights. Current Hypertension Reviews, 2020, 16, 12-18.	0.5	42
12	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. American Journal of Cardiology, 2020, 125, 887-893.	0.7	3
13	Coronary angiography and acute kidney injury: The dawn for novel markers. International Journal of Cardiology, 2020, 304, 175-176.	0.8	0
14	Coronary angiography and acute kidney injury: The dawn for novel markers. International Journal of Cardiology, 2020, 300, 119-120.	0.8	0
15	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. American Journal of Cardiology, 2020, 137, 133-135.	0.7	2
16	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. Journal of Human Hypertension, 2020, 34, 764-767.	1.0	25
17	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. Current Hypertension Reports, 2020, 22, 90.	1.5	35
18	COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. European Journal of Internal Medicine, 2020, 77, 153-155.	1.0	5

#	Article	IF	Citations
19	Update of the position paper on arterial hypertension and erectile dysfunction. Journal of Hypertension, 2020, 38, 1220-1234.	0.3	25
20	Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data. International Journal of Cardiology, 2020, 316, 240-241.	0.8	2
21	Pharmacological Management of Type 2 Diabetes Complications. Current Vascular Pharmacology, 2020, 18, 101-103.	0.8	6
22	Treatment strategies for hypertension in patients with type 1 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 1241-1252.	0.9	9
23	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and metaâ€analysis of randomized, shamâ€controlled, catheterâ€based trials. Journal of Clinical Hypertension, 2020, 22, 572-584.	1.0	29
24	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. Current Vascular Pharmacology, 2020, 18, 125-138.	0.8	9
25	Recent advances in understanding and managing resistant/refractory hypertension. F1000Research, 2020, 9, 169.	0.8	14
26	Dysmetabolic Iron Overload in Metabolic Syndrome. Current Pharmaceutical Design, 2020, 26, 1019-1024.	0.9	34
27	Microvascular Complications of Type 2 Diabetes Mellitus. Current Vascular Pharmacology, 2020, 18, 117-124.	0.8	235
28	Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis. Current Diabetes Reviews, 2020, 16, 313-326.	0.6	24
29	Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. Current Vascular Pharmacology, 2020, 19, 301-312.	0.8	8
30	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. Current Vascular Pharmacology, 2020, 19, 323-342.	0.8	15
31	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. Heart Failure Clinics, 2019, 15, 519-530.	1.0	2
32	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. Journal of Clinical Hypertension, 2019, 21, 1578-1579.	1.0	2
33	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. Journal of Sexual Medicine, 2019, 16, 1199-1211.	0.3	5
34	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. Expert Opinion on Drug Safety, 2019, 18, 241-251.	1.0	8
35	Insomnia and hypertension: A misty landscape. Journal of Clinical Hypertension, 2019, 21, 835-837.	1.0	3
36	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 158, 107927.	1.1	16

#	Article	IF	Citations
37	Determinants of pulse wave velocity index and potential implementations. Journal of Clinical Hypertension, 2019, 21, 1493-1495.	1.0	1
38	Is very low LDL-C harmful?. Current Pharmaceutical Design, 2019, 24, 3658-3664.	0.9	16
39	Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia. Current Pharmaceutical Design, 2019, 24, 3597-3598.	0.9	0
40	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2019, 24, 4587-4592.	0.9	42
41	The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. Current Pharmaceutical Design, 2019, 24, 5517-5524.	0.9	7
42	Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension. Current Pharmaceutical Design, 2019, 24, 5500-5507.	0.9	4
43	SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. Current Clinical Pharmacology, 2019, 13, 261-272.	0.2	13
44	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. Clinical and Molecular Hepatology, 2019, 25, 331-332.	4.5	0
45	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Polish Archives of Internal Medicine, 2019, 129, 648-650.	0.3	0
46	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. Journal of Clinical Hypertension, 2018, 20, 589-591.	1.0	1
47	Subclinical target organ damage in primary aldosteronism. Journal of Hypertension, 2018, 36, 701.	0.3	2
48	Carotid intimaâ€media thickness as a targetâ€organ damage and treatmentâ€target: Need for a major revision?. Journal of Clinical Hypertension, 2018, 20, 255-257.	1.0	4
49	Diabetes and lipid metabolism. Hormones, 2018, 17, 61-67.	0.9	192
50	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. Journal of Clinical Hypertension, 2018, 20, 634-636.	1.0	2
51	The potential role of statins in treating liver disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 331-339.	1.4	17
52	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. Journal of Clinical Hypertension, 2018, 20, 469-471.	1.0	2
53	Sacubitril/valsartan instead of reninâ€angiotensin system inhibition alone: A step forward in resistant hypertension. Journal of Clinical Hypertension, 2018, 20, 65-68.	1.0	9
54	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. Journal of Clinical Hypertension, 2018, 20, 942-948.	1.0	10

#	Article	IF	Citations
55	What is the role of statins in the elderly population?. Expert Review of Clinical Pharmacology, 2018, 11, 329-331.	1.3	1
56	Introducing In Vivo Dissection Modules for Undergraduate Level Trainees: What Is the Actual Benefit and How Could We Make It More Efficient?. Indian Journal of Surgery, 2018, 80, 68-76.	0.2	6
57	Antihypertensive drug treatment: the realâ€life challenge. Journal of Clinical Hypertension, 2018, 20, 115-117.	1.0	1
58	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. Open Cardiovascular Medicine Journal, 2018, 12, 29-40.	0.6	19
59	Editorial: Arterial Stiffness, Central Haemodynamics and Non-Alcoholic Fatty Liver Disease: Links with Cardiovascular Risk and Effects of Drug Treatment. Current Vascular Pharmacology, 2018, 16, 401-404.	0.8	15
60	Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 120-126.	0.2	5
61	Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 83-85.	0.2	0
62	Letter by Stavropoulos et al Regarding Article, â€œInfluence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Controlâ€. Circulation, 2018, 137, 2664-2665.	1.6	1
63	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Current Vascular Pharmacology, 2018, 16, 130-142.	0.8	54
64	Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis. Current Vascular Pharmacology, 2018, 16, 239-245.	0.8	13
65	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Current Vascular Pharmacology, 2018, 16, 246-253.	0.8	69
66	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. Current Vascular Pharmacology, 2018, 16, 276-288.	0.8	4
67	Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 104-113.	0.2	2
68	Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 94-103.	0.2	4
69	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 249-253.	0.9	45
70	Hematocrit and Stroke: A Forgotten and Neglected Link?. Seminars in Thrombosis and Hemostasis, 2017, 43, 591-598.	1.5	15
71	Blood pressure and cardiovascular outcomes: a closer look. Lancet, The, 2017, 389, 1295-1296.	6.3	1
72	Abnormal blood pressure dipping in diabetic kidney disease: A blackâ€race nightmare?. Journal of Clinical Hypertension, 2017, 19, 1336-1338.	1.0	3

#	Article	IF	Citations
73	The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology, 2017, 10, 1251-1261.	1.3	9
74	Testosterone Replacement Therapy and Cardiovascular Riskâ€"A Closer Look at Additional Parameters. JAMA Internal Medicine, 2017, 177, 1393.	2.6	2
75	Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?. Journal of Clinical Hypertension, 2017, 19, 798-800.	1.0	6
76	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. Current Pharmaceutical Design, 2017, 23, 1510-1521.	0.9	15
77	Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun. Current Pharmaceutical Design, 2017, 23, 1540-1550.	0.9	14
78	Letter by Imprialos et al Regarding Article, â€œPolypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillationâ€. Circulation, 2016, 134, e5-6.	1.6	0
79	Reninâ€Angiotensin System Inhibitors: Do They Have the Same Impact at All Ages?. Journal of Clinical Hypertension, 2016, 18, 828-828.	1.0	1
80	Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. Journal of Clinical Hypertension, 2016, 18, 1073-1073.	1.0	3
81	Echocardiographic Parameters During Long and Short Interdialytic Intervals in Hemodialysis Patients. American Journal of Kidney Diseases, 2016, 68, 772-781.	2.1	22
82	Depression in hypertensive patients. Journal of Hypertension, 2016, 34, 1441.	0.3	1
83	PATHWAY-2: spironolactone for resistant hypertension. Lancet, The, 2016, 387, 1371-1372.	6.3	0
84	Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. American Journal of Hypertension, 2016, 29, 662-662.	1.0	6
85	Discontinuation of Antihypertensive Treatment in Elderly Patients and Cognitive Function. JAMA Internal Medicine, 2016, 176, 409.	2.6	0
86	The Role of Mean Platelet Volume in Chronic Obstructive Pulmonary Disease Exacerbation. Respiratory Care, 2016, 61, 44-49.	0.8	19
87	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. Clinical Lipidology, 2016, 11, 2-5.	0.4	3
88	Sodiumâ€"glucose cotransporter-2 inhibitors and blood pressure decrease. Journal of Hypertension, 2015, 33, 2185-2197.	0.3	60